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SUMMARY
 
Expression of heat shock protein (HSP)-65 as well as infiltration of T-cells in arterial lesions and raised
levels of circulating antibodies against mycobacterial HSP65 (mHSP65) led us to the concept that
mHSP65 or its human homologue (hHSP60) might be involved in the etiopathogenesis of Takayasu’s
arteritis (TA). Therefore, we investigated mHSP65 and hHSP60 reactive peripheral blood T-cell subsets
by BrdU incorporation assay and flow cytometry as well as investigating the different isotypes of anti-
mHSP65 and hHSP60 antibodies by ELISA. Eighty-four percent (22/26) of the TA patients were
observed to show T-cell proliferation to mHSP65 and hHSP60 whereas only 16% (3/18) healthy controls
showed such proliferation (
 
P
 
 
 
<
 
 0·001). Both HSPs induced proliferation of exclusively CD4
 
+
 
 T-cells and
not CD8
 
+
 
 T-cells. We also observed a significantly higher prevalence of only the IgG isotype reactive to
mHSP65 and hHSP60 in TA as compared to HC (mHSP65: 92% TA 
 
versus
 
 11% HC, 
 
P
 
 
 
<
 
 0·0001 and
hHSP60: 84% 
 
versus
 
 22%, 
 
P
 
 
 
<
 
 0·001). Our data show a significant correlation between mHSP65 and
hHSP60 reactive T-cells (CD3
 
+
 
: 
 
r
 
 
 
=
 
 0·901; CD4
 
+
 
: 
 
r
 
 
 
=
 
 0·968) as well as anti-mHSP65 and anti-hHSP60
IgG antibodies (
 
r
 
 
 
=
 
 0·814) suggesting an infection induced autoimmunity in TA, possibly induced by
molecular mimicry between mHSP65 and hHSP60 or other tissue specific antigens.
 
Keywords
 
Takayasu’s arteritis mycobacterial HSP65 human HSP60 autoimmunity 
 
INTRODUCTION
 
Takayasu’s arteritis is a chronic granulomatous arteritis affecting
large elastic arteries, predominantly the aorta, its main branches,
and pulmonary and coronary arteries. Vascular inflammation cul-
minates in intimal thickening, fibrosis and stenosis with or without
thrombosis. This eventually results in end organ/tissue ischemia
and leads to different clinical manifestations of the disease [1–4].
The disease occurs more commonly in young females than males
with peak incidence between 15 and 20 years of age. It is the most
common vasculitic disorder in India and the third most common
vasculitis after Henoch-Schonlein purpura and Kawasaki disease
in the paediatric age group worldwide [5–7].
The aetiopathogenesis of TA is largely unknown but most of
the available data suggest that it is an autoimmune disease and
both cellular [8,9] as well as humoral [10–13] immune mechanisms
are involved in the pathogenesis of the disease. The increased
numbers of activated circulating T-cells [8] and their presence in
vascular lesions [9] suggest that T-cells have a primary role in
initiating the disease. However, the putative antigen(s) that trig-
ger activation and generation of these autoreactive T-cells are still
not known. 
 
Mycobacterium tuberculosis
 
 [14,15] has long been
implicated, as a possible aetiological agent in TA but there is no
convincing data for this. Expression of heat shock protein (HSP)-
65 as well as increased infiltration of T-cells in aortic tissue [16]
and raised levels of circulating antimycobacterial HSP65
(mHSP65) antibodies [17,18] in patients indicate that HSP65
whether exogenous or endogenous may be a putative antigen
stimulating immune responses in the disease. However, cellular
and humoral immune response to mHSP65 and its human homo-
logue, i.e. human heat shock protein-60 (hHSP60) has not yet
been evaluated in the disease.
Therefore in the present study, we undertook to investigate
the proliferative responses of different T-cell subsets as well as
different isotypes of antibodies to mHSP65 and hHSP60 in
patients with TA.
 
SUBJECTS AND METHODS
 
Subjects
 
Twenty-six patients with TA (20 female, 6 male; mean age
29·15 
 
±
 
 9·84 years; range 15–47 years) and 18 age/sex matched
healthy controls (HC) after obtaining their informed consent
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were enrolled in the study, which was approved by the Ethics
Committee of Sanjay Gandhi Post-graduate Institute of Medical
Sciences, Lucknow, India. All patients included in the study ful-
filled at least three of the classification and diagnostic criteria of
American College of Rheumatology, 1990 [19] and had an angio-
graphically proven disease.
Except three, all the patients included in the study were on
immunosuppressive therapy consisting of prednisolone and
azathioprine, which is given for 2 years with tapering of the pred-
nisolone dose as the disease become less active. The detailed clin-
ical data of the patients are given in Table 1.
 
Isolation and culture of peripheral blood mononuclear 
cells (PBMC)
 
After informed consent, 10 ml of venous blood was obtained
from each subject in a sterile glass tube containing 100 IU of
 
Table 1.
 
Clinical data of the patients
TA patient Age/sex Type of disease ESR (mm/h) CRP (mg/dl) Disease* activity Treatment (per day)
1 38/F III 35 10·55 Active Untreated
2 25/F III 51 12·24 Active Untreated
3 31/F III 47 8·35 Active Untreated
4 42/F I 44 5·03 Active Prednisolone 10 mg
Azathioprine 100 mg
5 28/M III 35 6·35 Active Prednisolone 10 mg
Azathioprine 100 mg
6 36/F III 25 0·25 Inactive Prednisolone 5 mg
Azathioprine 100 mg
7 24/F III 21
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
8 23/M III 35
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
9 14/F III 20
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
10 28/F III 22
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
11 47/M III 18
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
12 15/M III 35
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
13 42/F III 32
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
14 38/F III 32
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
15 25/M III 50 0·41 Inactive Prednisolone 5 mg
Azathioprine 100 mg
16 16/F III 48 0·47 Inactive Prednisolone 5 mg
Azathioprine 100 mg
17 22/F III 16 0·30 Inactive Prednisolone 5 mg
Azathioprine 100 mg
18 20/F III 15 0·31 Inactive Prednisolone 5 mg
Azathioprine 100 mg
19 23/M III 10 0·30 Inactive Prednisolone 5 mg
Azathioprine 100 mg
20 38/F I 25
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
21 42/F III 29 0·31 Inactive Prednisolone 5 mg
Azathioprine 100 mg
22 28/F III 25 0·69 Inactive Prednisolone 5 mg
Azathioprine 100 mg
23 42/F III 41 0·30 Inactive Prednisolone 5 mg
Azathioprine 100 mg
24 24/F III 16
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
25 33/F III 22
 
<
 
0·5 Inactive Prednisolone 5 mg
Azathioprine 100 mg
26 18/F III 9 0·33 Inactive Prednisolone 5 mg
Azathioprine 100 mg
*Disease activity was determined according to previously described criteria [39].
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heparin (Sigma, St Louis, MO, USA). Within 3 h of the sample
collection, PBMC were isolated by standard Ficoll-Hypaque
density gradient centrifugation method. The isolated cells were
washed twice with plain medium RPMI-1640 and finally resus-
pended at the concentration of 2 
 
¥
 
 10
 
6
 
 cells/ml in complete
medium consisting of RPMI-1640 supplemented with 3 m
 
M
 
 of
 
L
 
-glutamine, 10 m
 
M
 
 of HEPES buffer, 1 m
 
M
 
 of sodium pyru-
vate, 10% of heat inactivated fetal bovine serum and bacterio-
static level of penicillin-streptomycin (all from Gibco BRL,
USA). Cells were cultured in flat bottom 24 wells tissue culture
plate (Nunc, Roskilde, Denmark) at 1 ml/well in the absence or
presence of recombinant mHSP65 and hHSP60 (LIONEX
Diagnostics & Therapeutics GmbH, Braunschweig, Germany)
at the concentration of 10 
 
m
 
g/ml in a humidified environment at
37
 
∞
 
C with 5% CO
 
2
 
 in air for 72 h. During last 24 h the cells
were pulsed with 30 
 
m
 
g/ml of BrdU to allow its incorporation
into DNA of the proliferating cells.
 
Flow cytometric analysis of T-cell proliferation
 
Following the incorporation of BrdU, cells were harvested
directly in FACS tubes and washed once in PBS, fixed with
FACS Lysing solution and permeablized with 0·1% saponin for
15 min at room temperature. Thereafter 50 Kunitz U/ml
DNAse-I, activity 400–600 KU/ml protein (Sigma) dissolved in
Earl’s Balance Salt Solution (Gibco BRL, USA) was added.
DNA was digested for 10 min at 37
 
∞
 
C. Cells were washed,
resuspended in 100 
 
m
 
l PBS containing 2% bovine serum albu-
min and incubated with FITC-conjugated antibody to BrdU
(Becton Dickinson, CA, USA) at room temperature for 45 min.
Following this step cells were washed once in PBS-BSA; resus-
pended in 300 
 
m
 
l PBS-BSA; divided in three equal parts in dif-
ferent FACS tubes and immunostained with PE-conjugated
CD3, CD4 and CD8 monoclonal antibodies (Becton Dickin-
son) at room temperature for 30 min. Finally cells were washed
twice with PBS-BSA and resuspended in 500 
 
m
 
l of PBS contain-
ing 1% paraformaldehyde and analysed by flow cytometry
(FACS calibre, Becton Dickenson) using Cell-Quest software. A
subject was considered to have a positive T-cell proliferative
response to mHSP65 or hHSP60 if the percentage of BrdU pos-
itive T-cells of the subject was more than mean 
 
+
 
 2 standard
deviation (SD) of the BrdU positive T-cells of healthy controls
to a given HSP.
 
Detection of different isotypes of anti-HSP antibodies
 
Antibodies against mHSP65 and hHSP60 were investigated in the
sera of patients and controls by ELISA as described [18]. Briefly,
100 
 
m
 
l of 10 
 
m
 
g/ml of mHSP65/hHSP60 in carbonate-bicarbonate
buffer (pH 9·6) was added to each well of 96-well microtitre plates
(Nunc). Following overnight incubation at 4
 
∞
 
C, the plates were
washed thrice with PBS and blocked with 200 
 
m
 
l/well of PBS-BSA
(2% BSA) for 2 h at 37
 
∞
 
C. Plates were then washed with PBS con-
taining 0·05% Tween-20 (PBS-T). For detecting antibodies to
HSP, 1 : 200 dilution of test serum was used for IgG, IgM, and IgA
isotypes. One hundred microliters of the appropriately diluted
samples were added to the wells in duplicate and incubated for 1
h at 37
 
∞
 
C. Following washing with PBS-T, 100 
 
m
 
l/well of alkaline
phosphatase-conjugated rabbit anti-human IgG/IgM/IgA
(Sigma) diluted 1 : 2000 in PBS-BSA was added and incubated for
1 h at 37
 
∞
 
C. After washing with PBS-T, the colour reaction was
developed by adding 100 
 
m
 
l/well of p-nitrophenyl phosphate
(1 mg/ml, Sigma) and absorbance was read in an automated
ELISA reader (Tecan Spectra, Austria) at 405 nm. The cut off
value for stating that a sample is positive for HSP antibodies was
taken as mean 
 
+
 
 2SD of the optical densities (OD) of the normal
healthy controls.
 
Statistical analysis
 
Statistical comparisons between TA patients and healthy
controls for cellular proliferative responses and anti-HSP-
antibodies levels were performed by Mann–Whitney 
 
U
 
-test. Z-
statistics was used for comparing the prevalence between the
groups. Correlation analyses between HSP responses were done
by Spearman’s rank correlation test. The data was expressed as
mean 
 
±
 
 SD and a 
 
P
 
-value of 
 
<
 
0·05 was considered to be statisti-
cally significant.
 
RESULTS
 
Proliferative responses of T-cells to mHSP65 and hHSP60
 
Twenty-two out of 26 (84%) of the TA patients were observed to
have T-cell proliferation to mHSP65 and hHSP60 whereas, only 3
(16%) of 18 healthy controls showed T-cell proliferation
(
 
P
 
 
 
<
 
 0·001).
The magnitude of proliferative response of CD3
 
+
 
 T-cells to
mHSP65 and hHSP60 was significantly higher in patients as com-
pared to healthy controls (mHSP65: 14·72 
 
±
 
 9·98% 
 
versus
 
4·19 
 
±
 
 2·20%, 
 
P
 
 
 
<
 
 0·001 and hHSP60: 13·25 
 
±
 
 10·05% 
 
versus
 
3·71 
 
±
 
 1·51%, 
 
P
 
 
 
<
 
 0·001). Among the CD3
 
+
 
 T-cells, the percentage
of mHSP65 and hHSP60 reactive CD4+ T-cell was significantly
higher in patients as compared to the healthy controls (mHSP65:
11·10 
 
±
 
 8·26% 
 
versus
 
 3·49 
 
±
 
 1·55%, 
 
P
 
 
 
<
 
 0·001 and hHSP60:
10·67 
 
±
 
 8·50% 
 
versus
 
 3·30 
 
±
 
 1·20%, 
 
P
 
 
 
<
 
 0·001). However, CD8
 
+
 
 T-
cell showed no significant proliferation to any of the HSPs in both
groups (mHSP65: 3·15 
 
±
 
 2·85% 
 
versus
 
 2·85 
 
±
 
 0·89%, 
 
P
 
 
 
>
 
 0·05 and
hHSP60: 3·95 
 
±
 
 1·75% 
 
versus
 
 2·05 
 
±
 
 0·93%, 
 
P
 
 
 
>
 
 0·05).
Representative dot plots and box plot of CD3
 
+
 
 T-cells and
their CD4
 
+
 
 and CD8 
 
+
 
 subsets to mHSP65 and hHSP60 are pre-
sented as Figs 1 and 2, respectively.
 
Antibodies to mHSP65 and hHSP60
 
The prevalence of IgG anti-mHSP65 and IgG anti-hHSP60 anti-
bodies was significantly higher in TA as compared to healthy con-
trols (IgG-mHSP65: 92% (24/26) 
 
versus
 
 11% (2/18), 
 
P
 
 
 
<
 
 0·0001
and IgG-hHSP60: 84% (22/26) 
 
versus
 
 22% (4/18), 
 
P
 
 
 
<
 
 0·001).
There was no significant difference in the prevalence of IgM-
mHSP65 and IgM-hHSP60 isotype (IgM-mHSP65: 19% (5/26)
versus 11% (2/18), P > 0·05 and IgM-hHSP60: 15% (4/26) versus
11% (2/18), P > 0·05) as well as IgA-mHSP65 and IgA-hHSP60
isotype (IgA-mHSP65: 15% (4/26) versus 17% (3/18), P > 0·05
and IgA-hHSP60: 15% (4/26) versus 11% (2/18), P > 0·05)
between the groups.
Titers of IgG-mHSP65 and IgG-hHSP60 antibodies were also
significantly higher in patients as compared to controls (IgG-
mHSP65: 0·534 ± 0·343 versus 0·217 ± 0·111, P < 0·001 and IgG-
hHSP60: 0·769 ± 0·467 versus 0·330 ± 0·243, P < 0·001). The titres
of IgM-mHSP65 and IgM-hHSP60 [IgM-mHSP65: 0·225 ± 0·220
versus 0·178 ± 0·115, P = 0·400 and IgM-hHSP60: 0·219 ± 0·204
versus 0·166 ± 0·072, P = 0·890] as well as those of IgA-mHSP65
and IgA-hHSP60 (IgA-mHSP65: 0·237 ± 0·230 versus
0·182 ± 0·093, P = 0·789 and IgA-hHSP60: 0·233 ± 0·223 versus
0·184 ± 0·139, P < 0·797) antibodies in both the groups were com-
parable (Fig. 3).
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Correlation between responses to mHSP65 and hHSP60
A significant correlation between mHSP65 and hHSP60 reactive
T-cells (CD3+: r = 0·901; P < 0·001 and CD4+: r = 0·968; P < 0·001)
as well as anti-mHSP65 and anti-hHSP60 IgG antibodies
(r = 0·814; P < 0·001) were observed in patients with TA.
DISCUSSION
A number of immune abnormalities including increased number
of circulating activated T-cells [8,9], different autoantibodies [10–
13] and inflammatory cytokines [20,21] have been implicated in
the pathogenesis of TA. However, the initial stimulus that triggers
these immune abnormalities in the disease is not yet clear.
In the present study we have investigated T-cell proliferative
response and antibodies to mHSP65 as well as its 60 kD human
homologue in patients with TA. We observed mHSP65 and hHSP-
60 reactive T-cells as well as IgG anti-mHSP65 and IgG anti-
hHSP60 antibodies in most of the TA patients, suggesting the role
of mycobacterial HSP65 in the aetiology of the disease. To the
best of our knowledge, this is the first study reporting detection of
cellular and humoral responses to hHSP60 in TA and also first in
the detection of the immune responses to mHSP65 and hHSP60
simultaneously, enabling evaluation of correlation between cellu-
lar and humoral immune responses to both the HSPs.
The cellular response to a panel of mycobacterial antigens has
previously been studied in a single TA patient by Moraes et al.
[22]. These authors detected increased proliferation of peripheral
blood lymphocytes exclusively to mHSP65 and not to any other
mycobacterial antigens. However, they did not study the pheno-
types of proliferating lymphocytes. We have analysed prolifera-
tive response of CD3+ T-cells as well as their CD4+ and CD8+
subsets and observed that CD3+ and CD4+ T-cells exhibit a pro-
liferative response to mHSP65 as well as hHSP60. However, there
was no reactivity to either of the HSPs in the CD8+ T-cells. Sim-
ilar findings were also reported in other vasculitides including
Kawasaki disease and Behcet’s disease. In Kawasaki disease,
Sireci et al. [23] have shown clonal proliferation of CD4+ and
CD8+ T-cell  to  an  epitope  of  mHSP65,  spanning  amino  acid
Fig. 1. Representative flow cytometric dot plots showing proliferative response of CD3+ T-cells and their CD4+ and CD8+ subsets to
mycobacterial heat shock protein-65 (mHSP65) and human heat shock protein-60 (hHSP60) in patients with Takayasu’s arteritis (TA) and
healthy controls (HC). The proliferative response observed in TA as compared to HC to mHSP65 as well as hHSP60 was significantly
higher in (a) CD3+ T-cells and (b) CD4+ T-cells but not in (c) CD8+ T-cells.
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65–85. Direskeneli et al. [24] in Behcet’s disease reported an
enhanced T-cell reactivity to the eight synthetic peptides derived
from mHSP65 and hHSP60.
In another study on Behcet’s disease a significant fraction of
g d T-cell were shown to proliferate against mHSP65 [25].
Although, we have not evaluated proliferative responses of these
cells in our study but a proliferative response of a population of
CD3+ T-cells other than CD4+ and CD8+ T-cells points towards
proliferation of g d T-cells in TA. Expression of 65 kD heat shock
protein and increased infiltration of g d T-cell in arterial lesion of
TA also support this observation [16].
We also investigated T-cells reactivity to hHSP60, which
shows sequence homology with mHSP65 and found that prolifer-
ative responses of CD3+ T-cells as well as their CD4+ and CD8+
subsets were similar to the mHSP65 reactivity. There is no previ-
ous study on T-cells reactivity to hHSP60 in TA. However, in Beh-
cet’s disease increased T-cell response to 336–351 peptide
fragment of hHSP60 has been reported showing proliferation
exclusively of CD4+ T-cells and not of CD8+ T-cells [26].
In addition, we also investigated different isotypes of antibod-
ies reactive to mHSP65 and hHSP60 in the patients. We found
IgG antibodies to mHSP65 in 92% of patients. There are two pre-
vious studies on anti-mHSP65 antibodies in TA. In corroboration
with our findings, Hernandez-Pando et al. [17] have also reported
significantly raised IgG antibodies to mHSP65 in 78% patients
with TA. On the contrary, Aggarwal et al. [18] have detected
increased level of only IgA antibodies to mHSP65 in 91·6%
patients. One of the reasons for this difference between the data
of Aggarwal et al. [17] and that of Hernandez-Pando et al. [18] and
our may be due to existence of different isotypes of anti-HSP65
antibodies in different stages of the disease. Similar to our find-
ings, increased IgG anti-mHSP65 isotype have also been reported
in Kawasaki disease [27]. The existence of anti-hHSP60 antibod-
ies has not been studied in TA before. However, Yokota et al. [27]
have detected antibodies reactive to a specific epitope of human
HSP65 (equivalent to hHSP60) in Kawasaki disease but they did
not specify the isotypes. We have investigated IgG, IgM and IgA
isotypes of anti-hHSP60 antibodies and detected significant
increase in anti-hHSP60 IgG-isotype in TA.
The cellular and humoral immune responses observed in the
present study are not only specific to TA but have been docu-
mented in atherosclerosis [28,29] and other inflammatory autoim-
mune disorders as well [30,31]. We have also investigated immune
responses of TA patients to purified protein derivative (PPD) of
Mycobacterium tuberculosis as a control mycobacterial antigen
and observed that similar to HSP, most of the patients also have T-
Fig. 2. Dot-plots showing magnitude
of proliferative response of CD3+ T-
cells and their CD4+ and CD8+ subsets
to mycobacterial heat shock protein-65
(mHSP) and human heat shock pro-
tein-60 (hHSP) in patients with Taka-
yasu’s arteritis (TA) and healthy
controls (HC). The proliferative
response observed in TA as compared
to HC to mHSP65 as well as hHSP60
was significantly higher only in
CD3+ T-cells and CD4+ T-cells. Each
dot represents the data of an individual
subject and horizontal line crossing
dots represents mean percentage of
proliferative response in each group.
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cell and antibody reactivity to PPD (Unpublished Data). Similar
to our observation, studies in other vasculitides using PPD as a
control antigen have shown T-cell reactivity to mHSP65 as well as
to PPD [23].
An  important  finding  of  our  study  is  a  significant  correla-
tion between mHSP65 and hHSP60 reactive T-cells as well as
antibodies in the patients. These findings may suggest an infection-
induced autoimmunity in TA. Exposure of individuals to micro-
bial infections may be the primary pathogenic event in TA. The
immune response generated in the host against microbial HSP65,
which is an immunodominant antigen, may cross react with autol-
ogous HSP60 or other tissue-specific proteins containing similar
epitopes leading to development of autoimmunity to arterial com-
ponents. Increased expression of HSP65 in vascular lesions [16],
sequence homology of hHSP60 with variety of autoantigens [32]
and demonstration of mycobacterial antigen [14] as well as
Epstein-Barr virus [33] in arterial tissues support our hypothesis.
However, inflammation is another important factor that can lead
to tissue stress and consequently to up-regulation of HSP60
expression [34]. Thus the immune response to mycobacterial
HSP65 may also be due to raised responses to self HSP-60 [35].
There are reports in other autoimmune/inflammatory dis-
eases that HSP-reactive T-cells cause cytotoxicity of target cells
expressing HSP60 or other HSPs [36,37]. Similarly the HSP60/65
specific IgG antibodies have been shown to mediate cytotoxicity
of vascular endothelial cells in other vasculopathies [38]. We
although have not demonstrated the pathogenic relevance of HSP
reactive T-cells and IgG antibodies observed in the present study
but these studies and expression of HSP65 in the vascular lesions
in TA [16] together suggest an important role of these cellular and
humoral components in the disease. However, the exact patho-
genic role of HSP-reactive T-cells and antibodies is not known
and need to be investigated.
In conclusion, we have demonstrated the presence of T-cells
as well as IgG antibodies reactive to mHSP65 and its human
homologue suggesting that cross reactivity of immune response
between mHSP65 and hHSP60 or related arterial antigens may be
an important cause of development of autoimmunity in TA.
Future studies focused on cellular and humoral responses to spe-
cific epitopes of HSP65/60 and identification of homologous arte-
rial antigens would be important to delineate the exact
etiopathogenesis of the disease.
Fig. 3. Dot-plots showing levels of
IgG, IgM and IgA isotypes of antimy-
cobacterial heat shock protein-65
(mHSP) antibodies and anti-human
heat shock protein-60 (hHSP) antibod-
ies in patients with Takayasu’s arteritis
(TA) and healthy control (HC). The
levels of only IgG antibodies to both
the HSPs were significantly higher in
TA as compared to HC. Each dot rep-
resents data of an individual subject
and horizontal line crossing dots repre-
sents mean OD of each group.
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